Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Set to Reverse Split on Monday, October 26th

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) shares are scheduled to reverse split before the market opens on Monday, October 26th. The 1-8 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Biodexa Pharmaceuticals Stock Performance

BDRX opened at $0.42 on Thursday. The business has a fifty day moving average of $0.82 and a 200 day moving average of $2.17. Biodexa Pharmaceuticals has a 52-week low of $0.34 and a 52-week high of $44.70.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.

Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.